COMMUNIQUÉS West-GlobeNewswire

Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026
03/09/2026
Revenue increase driven by significant growth in the United States and other strategic markets NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “ [...]
University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
03/09/2026
University of Szeged installed Hungary’s first Robotic Magnetic Navigation system in July Over 70 patients with all forms of arrhythmia treated robotically to date, a record pace of use globally Robotics enabled [...]
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes
03/09/2026
Repurchase reduces unsecured note balance to approximately $364.7 million Management to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG, Md., Sept. 03, 2026 ( [...]
Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York
03/09/2026
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” [...]
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
03/09/2026
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious [...]
Crescent Biopharma to Present at September Investor Conferences
03/09/2026
WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
03/09/2026
Cette acquisition apporte au réseau de développement clinique précoce de Fortrea des compétences bioanalytiques dédiées et une capacité accrue alors que Worldwide poursuit sa stratégie visant à renforcer ses activités [...]
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026
03/09/2026
SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” [...]
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
03/09/2026
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly [...]
Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant
03/09/2026
European Investment Bank (EIB) convertible loan will help fund REGENERA™ development, CE marking, manufacturing scale-up and commercialization Follows positive 12-month pivotal trial data in July First EU regulatory [...]
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
03/09/2026
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in [...]
Commure Ambient AI Achieves Class I Certification and MHRA Registration
03/09/2026
AI-Powered Clinical Documentation Self-Certified for Immediate UK and EU Deployment MOUNTAIN VIEW, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Commure today announced that Commure Ambient AI , its widely deployed AI [...]
ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury
03/09/2026
The EIGER study will assess the safety and preliminary effectiveness of the investigational ARC-IM ® System to restore mobility after both subacute and chronic spinal cord injury ARC-IM is an implanted neuromodulation [...]
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
03/09/2026
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer’s Disease, a Progressive Neurodegenerative Disease TOKYO and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eisai [...]
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
03/09/2026
— Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (“ATTC”), which is expected to enter clinical trials in H2 2026 — — HUTCHMED webcasts today at 4:30 p.m. HKT in Chinese ( [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
02/09/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026
02/09/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 août 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
02/09/2026
Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. ( [...]
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09/2026
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]

Pages